참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 2,4-Dichloropyridine | HCID 33515 | — |
| 반응물 | 2-Methyl-2H-pyrazol-3-ylamine | HCID 136927 | — |
| 시약 | Sodium t-butoxide | HCID 23676156 | — |
| 촉매 | 1,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine) | HCID 636044 | — |
| 촉매 | Bis(dibenzylideneacetone)palladium | HCID 9811564 | — |
| 용매 | 1,4-Dioxane | HCID 31275 | — |
| 생성물 | 4-chloro-N-(2-methylpyrazol-3-yl)pyridin-2-amine | HCID 121439713 | 60.25% |
반응 단계
TRIS(DIBENZYLIDENEACETONE)DIPALLADIUM(0) (1.238 g, 1.35 mmol) was added in one portion to 2,4-dichloropyridine (10g, 67.57 mmol), 1-methyl-1H-pyrazol-5-amine (7.22 g, 74.33 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (2.346 g, 4.05 mmol) and sodium tert-butoxide (9.74 g, 101.36 mmol) in 1,4-dioxane (500 mL) warmed to 130ºC over a period of 10 minutes under nitrogen. The resulting mixture was stirred at 130 °C for 24 hours. The reaction mixture was evaporated to dryness and redissolved in DCM (300 mL), and washed with water (125 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 4% MeOH in DCM. Pure fractions were evaporated to dryness to afford EN01861-14-01 (2.93 g, 20.8 %) as a yellow crystalline solid. EN01861-14-01 (2.93 g) was combined with EN01861-09-01 (2.63g) to give EN01861-14-02 (5.56 g) as a yellow crystalline solid.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-dfcce3a0a05b417eb954f008fad9e74c |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|